Dr. Sotomayor on Differences Between FDA-Approved CAR T-Cell Therapies

Video

Eduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center, discusses differences between FDA-approved CAR T-cell therapies.

Eduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center, discusses differences between FDA-approved CAR T-cell therapies.

There are 2 FDA-approved CD19-directed CAR T-cell therapies: axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah). Both products are approved for the treatment of relapsed/refractory non-Hodgkin lymphoma, but tisagenlecleucel is also approved for pediatric patients with acute lymphoblastic leukemia. Although both products target CD19, they have different co-stimulatory domains, explains Sotomayor. CD28 is the costimulatory domain for axi-cel, whereas 4-1BB is the costimulatory domain for tisagenlecleucel. CAR T cells that rely on CD28 are more potent but have a shorter half-life, adds Sotomayor. Conversely, 4-1BB is less potent but has greater CAR T-cell persistence.

Now, researchers are investigating ways to extend the persistence of CD28 costimulatory products without decreasing efficacy. Research is also being dedicated to minimizing the toxicities associated with these products by modulating inflammatory cytokines, says Sotomayor. This approach may reduce the incidence of cytokine release syndrome and neurotoxicity.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.